Amarantus Bioscience Holdings Inc (AMBS)

[joboggi]

MJFF is firm with their notion that NFs have to go through an alpha syn model. That said, Jason has not considered this in his evaluation.

Now, it is most certainly true that AMBS will attract research dollars, so picking AMBS below the 200 day ma is probably a good idea.

Given the need to continue to fund the company by issuing shares, and the alpha syn issue I say that the fair value is somewhere around .12. That means a lot of people will be under water for a long time.

The key to buying biotech is getting it under the 200 day MA, and getting a LOT of them. Say probably 20. I cannot name the others, that would be off topic, but that is what you need to do.

The recent alpha syn study was necessary but bound to fail. Alpha syn is a natural product. Attacking it can only lead to a negative result. There are three mutant alpha syn forms that are involved in PD.

No one has attacked those mutant forms yet, and I am expecting them to do so at some point.

As best as I can evalutate, after reading all of the literature, MANF is a reactant to the inflammation and death caused by the mutant alpha syn. That means it helps a little in delaying the onset of PD, but ultimately fails because it does not attack the root cause. Difficulties with delivering MANF will more than likely keep it from being a disease modifier for PD.

However, it is reasonable to test MANF in primates to see what will happen. It is also reasonable to test it against Alpha syn. To that end, it will get research dollars.

However, all of the research regarding MANF treating chemically induced PD is obsolete now that we know how PD is caused. That includes all of the research reviewed by Jason. We've known about alpha syn for 10 years but for some reason the main focus of research has NOT gone through alpha syn. That has wasted a lot of money on GDNF and Neurturin.